Study of TP-06 for persistent corneal defects
This trial tests an experimental eye drop called TP-06 to see if it helps heal persistent corneal defects (areas of the eye's surface that won't close) that haven't improved with standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a persistent corneal defect (an open sore on the clear part of the eye) in one eye that hasn't healed after at least 10 days of standard care.
- The size of the defect must be stable (not getting bigger or smaller) between your first two study visits.
- No active eye infection in either eye.
- No corneal perforation (a hole in the cornea) or high risk of developing one.
- No severe eyelid problems that would affect healing.
- No eye or eyelid surgery in the study eye within 3 months before starting, unless the surgery caused the defect.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a treatment gel called NEXAGON (lufepirsen) can improve healing and safety in people with a persistent corneal problem called PCED that hasn’t gotten better despite standard non-surgical treatments. You may be a candidate if your defect has lasted at least 2 weeks and hasn’t improved recently, and if you don’t have certain eye infections or other eye conditions.
This study tests whether cenegermin eye drops help heal stubborn corneal ulcers (open sores on the clear front of the eye) that haven't improved with standard treatments like lubricating drops or contact lenses.
This study tests whether a special substance from stem cells (called secretome) can help heal chronic surface problems on the eye that haven't gotten better with standard treatments. It's for people with a stubborn scratch or defect on the cornea that has lasted more than 14 days.
This Phase 2 trial tests a locally delivered cell-based treatment (allogeneic mesenchymal stromal cells) to help heal long-lasting damage to the eye’s clear surface (the cornea). It may help if your cornea epithelium (surface layer) won’t improve even after standard non-surgical treatments.
This trial tests an experimental eye drop (STSP-0902) for a condition called neurotrophic keratitis, where the cornea (the clear front part of the eye) gets scratches or sores because nerves are damaged. The drop contains a growth factor to help the eye heal. You might be eligible if you have a persistent scratch or sore on your cornea that has not improved for at least a week.
This Phase 3 trial tests whether a 0.1% RGN-259 eye drop can safely improve a stubborn corneal wound in adults with neurotrophic keratopathy (nerve-related corneal healing problems). You may qualify if you still have an eye surface defect after at least a week of standard treatments, and you meet specific measurements for corneal sensitivity and vision.
Hear when a new Persistent Corneal Epithelial Defect trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.